RESUMEN
Patients with hypomorphic mutations in the RAG1 or RAG2 gene present with either Omenn syndrome or atypical combined immunodeficiency with a wide phenotypic range. Hematopoietic stem cell transplantation (HSCT) is potentially curative, but data are scarce. We report on a worldwide cohort of 60 patients with hypomorphic RAG variants who underwent HSCT, 78% of whom experienced infections (29% active at HSCT), 72% had autoimmunity, and 18% had granulomas pretransplant. These complications are frequently associated with organ damage. Eight individuals (13%) were diagnosed by newborn screening or family history. HSCT was performed at a median of 3.4 years (range 0.3-42.9 years) from matched unrelated donors, matched sibling or matched family donors, or mismatched donors in 48%, 22%, and 30% of the patients, respectively. Grafts were T-cell depleted in 15 cases (25%). Overall survival at 1 and 4 years was 77.5% and 67.5% (median follow-up of 39 months). Infection was the main cause of death. In univariable analysis, active infection, organ damage pre-HSCT, T-cell depletion of the graft, and transplant from a mismatched family donor were predictive of worse outcome, whereas organ damage and T-cell depletion remained significant in multivariable analysis (hazard ratio [HR] = 6.01, HR = 8.46, respectively). All patients diagnosed by newborn screening or family history survived. Cumulative incidences of acute and chronic graft-versus-host disease were 35% and 22%, respectively. Cumulative incidences of new-onset autoimmunity was 15%. Immune reconstitution, particularly recovery of naïve CD4+ T cells, was faster and more robust in patients transplanted before 3.5 years of age, and without organ damage. These findings support the indication for early transplantation.
Asunto(s)
Enfermedad Injerto contra Huésped , Trasplante de Células Madre Hematopoyéticas , Recién Nacido , Humanos , Donantes de Tejidos , Linfocitos T , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Diagnóstico Precoz , Costo de Enfermedad , Enfermedad Injerto contra Huésped/diagnóstico , Enfermedad Injerto contra Huésped/etiología , Estudios Retrospectivos , Donante no Emparentado , Acondicionamiento PretrasplanteRESUMEN
Adenovirus and Epstein-Barr virus can cause significant morbidity and mortality in paediatric patients post-bone marrow transplant. The source of infection is thought to be either reactivation of latent viruses or primary infection. We have investigated whether transfusion of blood components from viraemic donors could provide a route of primary infection in these patients and sought the prevalence of viraemia in the blood donor population from England. In 32 linked donor/recipient samples and 300 unselected blood donors, we found no evidence to suggest that these infections in paediatric bone marrow transplant recipients had been acquired from transfused blood components.
Asunto(s)
Adenoviridae/genética , Trasplante de Médula Ósea , ADN Viral/análisis , Herpesvirus Humano 4/genética , Adenoviridae/aislamiento & purificación , Infecciones por Adenoviridae/transmisión , Infecciones por Adenoviridae/virología , Transfusión de Componentes Sanguíneos , Donantes de Sangre , Ensayo de Inmunoadsorción Enzimática , Infecciones por Virus de Epstein-Barr/transmisión , Infecciones por Virus de Epstein-Barr/virología , Herpesvirus Humano 4/aislamiento & purificación , Humanos , Reacción en Cadena en Tiempo Real de la PolimerasaRESUMEN
Haematopoietic stem cell transplantation (HSCT) can be a curative procedure for a growing number of paediatric diseases, but as the indications for HSCT grow, so does the need to find suitable stem cell donors. When the preferred option of a genoidentical sibling donor is not available alternative donors, including unrelated adult or umbilical cord blood donors, or haploidentical related donors may be considered. Outcome following alternative donor HSCT has improved over the past 20 years but graft-versus-host disease (GvHD) remains a significant obstacle. T cell depletion (TCD) for non-genoidentical grafts aims to reduce the morbidity and mortality associated with GvHD, but this intervention has not led directly to improved survival due to delayed immune reconstitution and increased infections, graft rejection and increased rates of disease relapse. Limited data from the paediatric population, however, suggest some encouraging results for children undergoing haploidentical HSCT: a move from positive selection of CD34(+) haematopoietic stem cells towards negative depletion of specific cell subsets in order to retain useful accessory cells within the graft appears to enhance immune reconstitution and improve disease-free survival. Here we review recent paediatric outcome data for T cell-depleted HSCT, explore the role of serotherapy in conditioning regimens and look at future possibilities to improve outcome, including novel allodepletion techniques, suicide gene therapy and pathogen-specific immunotherapy.
Asunto(s)
Enfermedad Injerto contra Huésped/inmunología , Trasplante de Células Madre Hematopoyéticas , Depleción Linfocítica , Subgrupos de Linfocitos T/inmunología , Linfocitos T/inmunología , Antígenos CD34/metabolismo , Niño , Supervivencia sin Enfermedad , Sangre Fetal/trasplante , Rechazo de Injerto , Humanos , Acondicionamiento Pretrasplante , Trasplante Homólogo/inmunologíaRESUMEN
This report describes a case of juvenile myelomonocytic leukaemia (JMML) on a background of both perinatally acquired HIV infection and congenital cytomegalovirus, and management of antiretroviral therapy during haematopoietic stem cell transplant. Peripheral blood HIV viral load remained below the lower limit of detection throughout and following transplant and is currently <20 RNA copies/mL. The child is currently in remission from JMML, but HIV DNA remains detectable despite myeloablative conditioning and sustained plasma HIV viral suppression.
RESUMEN
Glanzmann thrombasthenia (GT) is a rare autosomal recessive platelet function disorder. Stem cell transplantation (SCT) is curative, but it is only indicated in selected patients with a severe clinical phenotype or who develop anti-platelet antibodies. SCT have previously been limited to full intensity myeloablative conditioning regimens. This study details the successful outcome of SCT in five consecutive patients with GT, three of whom received reduced intensity conditioning (RIC) with stem cells from non-sibling donors. This is the first time RIC SCT has been reported in GT, and offers the possibility of curative therapy with reduced late effects.
Asunto(s)
Trasplante de Células Madre/métodos , Trombastenia/terapia , Niño , Preescolar , Femenino , Supervivencia de Injerto , Enfermedad Injerto contra Huésped , Humanos , Masculino , Quimera por Trasplante , Acondicionamiento Pretrasplante/métodos , Resultado del TratamientoRESUMEN
Allogeneic hematopoietic SCT is well established as a potentially curative therapy for children and adults with both malignant and nonmalignant diseases. However, myeloablative SCT is associated with significant short- and long-term complications. The goals of a reduced intensity-conditioning (RIC) regimen are to prevent graft rejection and establish stable donor-derived hematopoiesis at a level sufficient for cure of the underlying disease and, in patients with hematologic malignancy, to provide a GVL effect, while decreasing the short- and long-term complications associated with myeloablative conditioning therapy. RIC regimens have enabled SCT to be performed in children with preexisting comorbidities that preclude conventional conditioning. RIC-SCT has been most extensively studied in patients with nonmalignant disorders and for some of these, including primary immunodeficiencies and hemophagocytic lymphohistiocytosis, sufficient data now exist to support its routine use even in patients without comorbidity. Less data exist on RIC-SCT for children with hematologic malignancies and at present this should be restricted to children who are not candidates for, or have relapsed after, myeloablative SCT. Here we review available data on the use of RIC-SCT in pediatric patients, highlighting important clinical lessons and areas that require further study.
Asunto(s)
Supervivencia de Injerto , Trasplante de Células Madre Hematopoyéticas/métodos , Acondicionamiento Pretrasplante/métodos , Niño , Efecto Injerto vs Tumor , Humanos , Estimación de Kaplan-Meier , Quimera por Trasplante , Trasplante Homólogo/métodosRESUMEN
We report successful outcome in 13 children (median age 2.2 years) with high-risk AML who received SCT from an unrelated (11) or identical sibling (2) donor after a preparative regimen consisting of BU, CY and melphalan. Three children were 'poor'-risk in first CR, three in the second CR, five in PR and two had resistant disease. Immunotherapeutic strategies were employed to maximize a GVL response escalating through a reduced dose of alemtuzumab, early taper of CsA, donor lymphocyte infusion and treatment with alpha-IFN. Ten out of 13 (77%) children are alive in CR at a median of 41 months (range: 17-88) from SCT. There was no TRM, but three children relapsed and died 3, 4 and 17 months after SCT. These encouraging early results warrant further studies in children with very high-risk AML.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Leucemia Mieloide Aguda/tratamiento farmacológico , Trasplante de Células Madre/métodos , Acondicionamiento Pretrasplante/métodos , Alemtuzumab , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales Humanizados , Anticuerpos Antineoplásicos/uso terapéutico , Busulfano/uso terapéutico , Niño , Preescolar , Terapia Combinada , Ciclofosfamida/uso terapéutico , Ciclosporina/uso terapéutico , Femenino , Enfermedad Injerto contra Huésped/prevención & control , Humanos , Inmunoterapia , Lactante , Masculino , Melfalán/uso terapéutico , Quimera por Trasplante/inmunología , Trasplante HomólogoRESUMEN
Feed sustainability is one of the biggest challenges for the next few years. Solutions have to be found that take feed quality and safety into account. Animal by-products are one valuable source of proteins. However, since the bovine spongiform encephalopathy (BSE) crisis, their use has been strictly regulated. The objective of this study was to propose a routine, sensitive and specific method using ultra-high performance liquid chromatography coupled to tandem mass spectrometry for the detection of blood-derived products and milk powder in feed. Contaminated aquafeeds were analysed in order to evaluate the sensitivity and specificity of the method. This new method meets both selectivity and sensitivity (0.1% (w/w)) requirements imposed by the European Commission for animal proteins detection methods. It offers an innovative and complementary solution for the simultaneously identification of authorised and unauthorised animal by-products such as processed animal proteins (PAPs).
Asunto(s)
Alimentación Animal/análisis , Sangre , Límite de Detección , Leche/química , Espectrometría de Masas en Tándem/métodos , Animales , Bovinos , Cromatografía Líquida de Alta Presión , Contaminación de Alimentos/análisis , Factores de TiempoRESUMEN
We reviewed outcomes after allogeneic hematopoietic cell transplantation (HCT) in 35 children with Chediak-Higashi syndrome (CHS). Twenty-two patients had a history of the life-threatening accelerated phase of CHS before HCT and 11 were in accelerated phase at transplantation. Thirteen patients received their allograft from an human leukocyte antigen (HLA)-matched sibling, 10 from an alternative related donor and 12 from an unrelated donor. Eleven recipients of HLA-matched sibling donor, three recipients of alternative related donor and eight recipients of unrelated donor HCT are alive. With a median follow-up of 6.5 years, the 5-year probability of overall survival is 62%. Mortality was highest in those with accelerated phase disease at transplantation and after alternative related donor HCT. Only four of 11 patients with active disease at transplantation are alive. Seven recipients of alternative related donor HCT had active disease at transplantation and this may have influenced the poor outcome in this group. Although numbers are limited, HCT appears to be effective therapy for correcting and preventing hematologic and immunologic complications of CHS, and an unrelated donor may be a suitable alternative for patients without an HLA-matched sibling. Early referral and transplantation in remission after accelerated phase disease may improve disease-free survival.
Asunto(s)
Síndrome de Chediak-Higashi/terapia , Trasplante de Células Madre Hematopoyéticas/métodos , Adolescente , Niño , Preescolar , Supervivencia sin Enfermedad , Femenino , Estudios de Seguimiento , Enfermedad Injerto contra Huésped , Antígenos HLA/biosíntesis , Células Madre Hematopoyéticas/citología , Humanos , Masculino , Estudios Retrospectivos , Trasplante Homólogo , Resultado del TratamientoRESUMEN
This paper describes the trends in haematopoietic stem cell transplantation (HSCT) activity for children in Europe over the last three decades. We analysed 31,713 consecutive paediatric HSCTs reported by the European Group for Blood and Marrow Transplantation (EBMT) centres between 1970 and 2002. Data were taken from the EBMT registry and were compared according to period and centre category (paediatric or combined). Since 1996, there has been a significant increase in the number of HSCTs performed exclusively by paediatric centres, as well as in the number of alternative donor HSCTs, and in the use of peripheral blood stem cells (P<0.0001). The number of allogeneic HSCTs (allo-HSCTs) for acute lymphoblastic leukaemia, acute myeloblastic leukaemia and chronic myeloid leukaemia remained stable, whereas it increased for myelodysplastic syndromes and lymphomas, and decreased significantly for non-malignant diseases (P<0.0001). Multivariate analysis showed that younger age, human leukocyte antigen genoidentical donors, HSCT performed after 1996 and transplant centres performing more than 10 allo-HSCT/year were all associated with decreased transplant-related mortality (TRM) (P<0.0001). The number of autologus HSCTs (auto-HSCTs) for acute leukaemia decreased significantly, whereas it increased for solid tumours (P<0.0001). Multivariate analysis showed that both auto-HSCT performed before 1996 and paediatric solid tumours (P<0.0001) had higher TRM. Indications for paediatric HSCT have changed considerably during the last seven years. These changes provide tools for decision making in health-care planning and counselling.
Asunto(s)
Trasplante de Células Madre Hematopoyéticas/estadística & datos numéricos , Transfusión Sanguínea/estadística & datos numéricos , Trasplante de Médula Ósea/estadística & datos numéricos , Niño , Recolección de Datos , Europa (Continente) , Humanos , Leucemia/terapia , Sistema de Registros , Trasplante Autólogo , Trasplante HomólogoRESUMEN
Hurler's syndrome (HS), the most severe form of mucopolysaccharidosis type-I, causes progressive deterioration of the central nervous system and death in childhood. Allogeneic stem cell transplantation (SCT) before the age of 2 years halts disease progression. Graft failure limits the success of SCT. We analyzed data on HS patients transplanted in Europe to identify the risk factors for graft failure. We compared outcomes in 146 HS patients transplanted with various conditioning regimens and grafts. Patients were transplanted between 1994 and 2004 and registered to the European Blood and Marrow Transplantation database. Risk factor analysis was performed using logistic regression. 'Survival' and 'alive and engrafted'-rate after first SCT was 85 and 56%, respectively. In multivariable analysis, T-cell depletion (odds ratio (OR) 0.18; 95% confidence interval (CI) 0.04-0.71; P=0.02) and reduced-intensity conditioning (OR 0.08; 95% CI 0.02-0.39; P=0.002) were the risk factors for graft failure. Busulfan targeting protected against graft failure (OR 5.76; 95% CI 1.20-27.54; P=0.028). No difference was noted between cell sources used (bone marrow, peripheral blood stem cells or cord blood (CB)); however, significantly more patients who received CB transplants had full-donor chimerism (OR 9.31; 95% CI 1.06-82.03; P=0.044). These outcomes may impact the safety/efficacy of SCT for 'inborn-errors of metabolism' at large. CB increased the likelihood of sustained engraftment associated with normal enzyme levels and could therefore be considered as a preferential cell source in SCT for 'inborn errors of metabolism'.
Asunto(s)
Rechazo de Injerto/mortalidad , Trasplante de Células Madre Hematopoyéticas , Mucopolisacaridosis I/mortalidad , Busulfano/administración & dosificación , Niño , Preescolar , Bases de Datos Factuales , Supervivencia sin Enfermedad , Europa (Continente) , Femenino , Rechazo de Injerto/etiología , Supervivencia de Injerto/efectos de los fármacos , Humanos , Lactante , Recién Nacido , Modelos Logísticos , Depleción Linfocítica/efectos adversos , Masculino , Mucopolisacaridosis I/terapia , Agonistas Mieloablativos/administración & dosificación , Estudios Retrospectivos , Factores de Riesgo , Tasa de Supervivencia , Quimera por Trasplante , Acondicionamiento Pretrasplante/efectos adversos , Trasplante HomólogoRESUMEN
A multicenter field efficacy study was performed in six farms located in Belgium, France and Germany with a history of suspected coccidiosis outbreaks and the proven presence of Eimeria bovis and/or Eimeria zuernii. At each of these trial sites the calves were randomly allocated to two groups (T, treated; C, control) of similar size. In total, 231 calves were included in the study. Group T calves (n=116) were drenched with a single dose of diclazuril (Vecoxan, 1mg/kg body weight) close to the time of expected outbreak of coccidiosis (day 1 of the study period), group C calves (n=115) served as placebo-treated controls. Although E. bovis and/or E. zuernii were identified at all trial sites, clinical coccidiosis was only noted in 16% of the group C calves. At day 5 of the study period (4 days after treatment), faecal oocyst counts (opg, oocysts per gram) were substantially lower in group T ("short-term effect") compared to group C. At four trial sites, the respective values of groups T and C were significantly different (P=0.0132 to P=0.0001) in favour of group T. For the pooled data of all trial sites, this effect was highly significant (P<0.0001). The overall faecal oocyst counts from day 3 until day 21 of the study period ("Area Under the Curve") was significantly reduced in group T by 87.2-99.5% ("long-term effect") at five trial sites (P=0.0139 to P<0.0001). The pooled data revealed a highly significant effect of treatment on oocyst excretion over the observation period (P<0.0001). On five of the six trial sites, the average weight gain was higher in group T than in group C. On those trial sites, the average weight gain of group T calves exceeded that of the controls by 95-268g/day and by 2.0-6.0kg over the study period. This effect was statistically significant (P<0.01) at one trial site. Altogether the calves of group T gained on average 129g more weight daily than the controls (+2.7kg over the study period). For these pooled data, statistical analysis confirmed the positive effect of treatment of calves exposed to coccidiosis on growth performance (P=0.003). In conclusion, metaphylactic treatment with diclazuril efficiently controls coccidiosis in calves thus reducing environmental contamination with oocysts and preventing negative effects of natural exposure to coccidiosis on growth performance of calves.
Asunto(s)
Enfermedades de los Bovinos/tratamiento farmacológico , Enfermedades de los Bovinos/parasitología , Bovinos/crecimiento & desarrollo , Coccidiosis/veterinaria , Coccidiostáticos/uso terapéutico , Eimeria/fisiología , Nitrilos/uso terapéutico , Oocistos/efectos de los fármacos , Triazinas/uso terapéutico , Animales , Coccidiosis/tratamiento farmacológico , Coccidiosis/parasitología , Heces/parasitología , Femenino , Masculino , Oocistos/fisiologíaRESUMEN
Hematopoietic stem cell transplantation (HSCT) is an increasingly common treatment for children with a range of hematological disorders. Conditioning with cytotoxic chemotherapy and total body irradiation leaves patients severely immunocompromised. T-cell reconstitution can take several years due to delayed restoration of thymic output. Understanding T-cell reconstitution in children is complicated by normal immune system maturation, heterogeneous diagnoses, and sparse uneven sampling due to the long time spans involved. We describe here a mechanistic mathematical model for CD4 T-cell immune reconstitution following pediatric transplantation. Including relevant biology and using mixed-effects modeling allowed the factors affecting reconstitution to be identified. Bayesian predictions for the long-term reconstitution trajectories of individual children were then obtained using early post-transplant data. The model was developed using data from 288 children; its predictive ability validated on data from a further 75 children, with long-term reconstitution predicted accurately in 81% of the patients.
Asunto(s)
Linfocitos T CD4-Positivos/metabolismo , Trasplante de Células Madre Hematopoyéticas/tendencias , Modelos Biológicos , Linfocitos T CD4-Positivos/inmunología , Niño , Preescolar , Femenino , Estudios de Seguimiento , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Humanos , Lactante , Recién Nacido , Masculino , Valor Predictivo de las Pruebas , Timo/efectos de los fármacos , Timo/inmunología , Timo/metabolismo , Acondicionamiento Pretrasplante/efectos adversos , Acondicionamiento Pretrasplante/tendenciasRESUMEN
We report outcomes for 44 children who underwent stem cell transplantation (SCT) for refractory AML in the UK between 2000 and 2012. Median age at SCT was 11.5 years. Twenty-three patients had primary refractory and 21 relapsed refractory AML. Refractory disease was confirmed by cytogenetics/molecular genetics in 24 cases. Median follow-up of the whole cohort is 6.8 years (2.1-14.9 years). Thirty patients (68%) achieved a CR following SCT. Transplant-related mortality at 1 year was 18%. Acute GVHD incidence was 52% (grade ⩾III 19%), chronic 7%. Relapse was the major cause of treatment failure and occurred in 32% of patients at a median of 61 days post SCT. Five-year overall survival and leukemia-free survival (LFS) were 43% (95% CI 31-61%). All patients with favorable cytogenetics (n=6) are alive in CR. Outcomes in patients with primary refractory disease were equivalent to those with relapsed refractory AML. Blast percentage ⩽30% in the BM pre-SCT, myeloablative conditioning and acute GVHD proved to be favorable prognostic features. We could stratify patients according to age ⩾10 years and >30% blasts in BM pre-SCT. Patients with none/one of these risk factors were highly salvageable (5 years LFS 53%) whereas those with both factors had a very poor prognosis (5 years LFS 10%). This may facilitate decision making on whether it is appropriate to consider transplant in such patients.
Asunto(s)
Enfermedad Injerto contra Huésped/mortalidad , Trasplante de Células Madre Hematopoyéticas , Leucemia Mieloide Aguda/mortalidad , Leucemia Mieloide Aguda/terapia , Enfermedad Aguda , Adolescente , Aloinjertos , Niño , Preescolar , Aberraciones Cromosómicas , Supervivencia sin Enfermedad , Femenino , Estudios de Seguimiento , Enfermedad Injerto contra Huésped/genética , Enfermedad Injerto contra Huésped/patología , Humanos , Leucemia Mieloide Aguda/genética , Leucemia Mieloide Aguda/patología , Masculino , Recurrencia , Tasa de Supervivencia , Reino Unido/epidemiologíaRESUMEN
Trials with second generation CD19 chimeric antigen receptors (CAR) T-cells report unprecedented responses but are associated with risk of cytokine release syndrome (CRS). Instead, we studied the use of donor Epstein-Barr virus-specific T-cells (EBV CTL) transduced with a first generation CD19CAR, relying on the endogenous T-cell receptor for proliferation. We conducted a multi-center phase I/II study of donor CD19CAR transduced EBV CTL in pediatric acute lymphoblastic leukaemia (ALL). Patients were eligible pre-emptively if they developed molecular relapse (>5 × 10-4) post first stem cell transplant (SCT), or prophylactically post second SCT. An initial cohort showed poor expansion/persistence. We therefore investigated EBV-directed vaccination to enhance expansion/persistence. Eleven patients were treated. No CRS, neurotoxicity or graft versus host disease (GVHD) was observed. At 1 month, 5 patients were in CR (4 continuing, 1 de novo), 1 PR, 3 had stable disease and 3 no response. At a median follow-up of 12 months, 10 of 11 have relapsed, 2 are alive with disease and 1 alive in CR 3 years. Although CD19CAR CTL expansion was poor, persistence was enhanced by vaccination. Median persistence was 0 (range: 0-28) days without vaccination compared to 56 (range: 0-221) days with vaccination (P=0.06). This study demonstrates the feasibility of multi-center studies of CAR T cell therapy and the potential for enhancing persistence with vaccination.
Asunto(s)
Antígenos CD19 , Inmunoterapia Adoptiva , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Receptores de Antígenos de Linfocitos T/genética , Linfocitos T Citotóxicos/trasplante , Niño , Preescolar , Quimera , Femenino , Herpesvirus Humano 4 , Humanos , Inmunoterapia/métodos , Masculino , Receptores de Antígenos de Linfocitos T/inmunología , Recurrencia , Linfocitos T Citotóxicos/virología , VacunaciónRESUMEN
Hurler syndrome (MPS 1H) is the severe form of mucopolysaccharidosis type 1 (MPS 1). Haematopoietic cell transplantation (HCT) is the treatment of choice, but carries a high incidence of graft failure and morbidity. The use of enzyme replacement therapy (ERT) might improve the clinical signs and symptoms before HCT, resulting in less transplantation-related complications. Moreover, clearance of glycosaminoglycans (GAG's) from the bone marrow might improve engraftment. Twenty-two patients with MPS 1H received one or more HCT procedures in combination with ERT. One patient with severe cardiomyopathy improved significantly after ERT. All children were in a relatively good clinical condition before HCT. Of patients 59, 82 and 86% were alive and engrafted after one, two and three HCT procedures, respectively. Two patients died after repetitive HCT. No serious ERT-infusion-related toxicity occurred. ERT with HCT was well tolerated. Neither a positive nor a negative effect on the number of patients who are alive and engrafted after receiving ERT before HCT as compared to a historic cohort was noted. However, patients in a poor clinical condition before HCT might benefit from ERT.
Asunto(s)
Trasplante de Células Madre Hematopoyéticas , Iduronidasa/uso terapéutico , Mucopolisacaridosis I/terapia , Preescolar , Terapia Combinada/métodos , Estudios de Seguimiento , Enfermedad Injerto contra Huésped/diagnóstico , Enfermedad Injerto contra Huésped/terapia , Humanos , Iduronidasa/administración & dosificación , Lactante , Mucopolisacaridosis I/diagnóstico , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/uso terapéutico , Resultado del TratamientoRESUMEN
The influence of three variables, i.e. the concentrations of benzyl alcohol (BA), butylated hydroxytoluene (BHT) and tert-butyl-4-hydroxyanisol (BHA), on the preservative efficacy and antioxidant activity of an oily veterinary formulation was investigated using quantitative experimental designs and applying pharmacopoeial methods as part of the robustness-evaluation. Preservative Efficacy Tests (PETs) were performed using the validated European Pharmacpoeia (EP) methodology with 7 test-organisms over one month on lab-scale test-formulations. These were independently prepared according to a Box-Behnken experimental design with a triplicate central point at 0.75% m/V BA, 0.05% mN BHT and 0.05% m/V BHA, and with an additional control-point outside the Box-Behnken cube containing no preservative ingredient. The preservative efficacies were evaluated against the USP and EP criteria for formulations for oral use, as well as by the statistical comparison of the slopes obtained by linear regression of the log of CFU/g versus time. The peroxide values were determined after two months storage at 50 degrees C, using the EP titrimetric method. No interactions between the preservatives were observed for any of the seven tested micro-organisms in the PETs. BA had a very significant preservative effect against several of the tested microorganisms, while no antimicrobial effect for BHT and BHA was observed. Aspergillus niger was the most preservative-resistant micro-organism, while Staphylococcus aureus was the most sensitive test-germ. Compliance with USP-PET criteria was found for all formulations tested, even those without preservatives, while the EP-PET criteria showed compliance for those formulations with the highest BA concentration only. Stored in glass vials, a statistically significant antioxidant effect was demonstrated for BA only, although all tested formulations showed acceptable anti-oxidative properties. No significant antioxidant effects were shown for BHT or BHA.
Asunto(s)
Aceites/química , Conservadores Farmacéuticos/química , Antibacterianos/química , Antibacterianos/farmacología , Antifúngicos/química , Antifúngicos/farmacología , Antioxidantes/química , Antioxidantes/farmacología , Bacterias/efectos de los fármacos , Química Farmacéutica , Recuento de Colonia Microbiana , Medios de Cultivo , Hongos/efectos de los fármacos , Modelos Lineales , Conservadores Farmacéuticos/farmacología , Reproducibilidad de los Resultados , Drogas Veterinarias/químicaRESUMEN
Animal by-products are valuable protein sources in animal nutrition. Among them are blood products and blood meal, which are used as high-quality material for their beneficial effects on growth and health. Within the framework of the feed ban relaxation, the development of complementary methods in order to refine the identification of processed animal proteins remains challenging. The aim of this study was to identify specific biomarkers that would allow the detection of bovine blood products and processed animal proteins using tandem mass spectrometry. Seventeen biomarkers were identified: nine peptides for bovine plasma powder; seven peptides for bovine haemoglobin powder, including six peptides for bovine blood meal; and one peptide for porcine blood. They were not detected in several commercial compound feed or feed materials, such as blood by-products of other animal origins, milk-derived products and fish meal. These biomarkers could be used for developing a species-specific and blood-specific detection method.
Asunto(s)
Alimentación Animal/análisis , Proteínas Sanguíneas/análisis , Espectrometría de Masa por Ionización de Electrospray/métodos , Espectrometría de Masas en Tándem/métodos , Secuencia de Aminoácidos , Animales , Biomarcadores/análisis , Biomarcadores/sangre , Proteínas Sanguíneas/genética , Bovinos , Cromatografía Líquida de Alta Presión/métodos , Productos Lácteos/análisis , Encefalopatía Espongiforme Bovina/diagnóstico , Encefalopatía Espongiforme Bovina/prevención & control , Contaminación de Alimentos/análisis , Hemoglobinas/análisis , Hemoglobinas/genética , Aves de Corral , Especificidad de la Especie , PorcinosRESUMEN
PURPOSE: This study sought to determine whether the identification of minimal pulmonary metastatic disease by chest computed tomography (CT) performed at diagnosis in patients with Wilms' tumor and normal chest x-rays (CXR) could predict a subgroup of children at increased risk of pulmonary relapse. PATIENTS AND METHODS: A retrospective analysis was carried out of the records of 449 children entered onto the United Kingdom Childrens' Cancer Study Group Second Wilms' Tumor Study between July 1986 and September 1991. The imaging protocol did not stipulate chest CT at diagnosis, but 141 children who had normal frontal and lateral CXRs and a chest CT scan performed at diagnosis were eligible for analysis. After surgery, children with stage I Wilms' tumor received single-agent chemotherapy (vincristine), whereas children with stages II, III, and bilateral Wilms' tumor received combination chemotherapy. Most children with stage III tumors were also treated with abdominal radiotherapy (20 Gy). RESULTS: In 31 patients (22%), pulmonary nodules were visible on chest CT; eight experienced relapse, four (15%) in the lungs. When only stage I patients were analyzed, there was a significant difference between the pulmonary relapse rate of 43% (three of seven) in the CT-positive group and 10% (five of 48) in the CT-negative group (P =.02). Four of eight patients with stage I disease with pulmonary relapse died. CONCLUSION: CT seemed to identify a subgroup of stage I patients who were at increased risk of pulmonary relapse. These children had received only single-agent chemotherapy. A prospective randomized trial is needed to clarify whether these children would benefit from combination chemotherapy.